First Trade Date for Protein Design Labs, Inc.
| Company Name | First Trade Date (yyyy-mm-dd) |
| Protein Design Labs, Inc. | 1992-01-29 |
| Company Name | Symbol |
| Protein Design Labs, Inc. | PDLI |
| History and Business of Company (this information may include date of incorporation) | |
|
Protein Design Labs, Inc. (PDLI) aims to leverage its product pipeline and intellectual property with the goal of becoming a profitable, fully integrated biopharmaceutical concern. Its major revenue sources are sales of developed products, royalties from the sale of antibodies developed by other companies using PDLI patents, and research and development contracts with other companies. Therapeutics currently being developed using PDLI's SMART humanized antibodies include treatments for autoimmune and inflammatory disorders, organ transplantation, and cancer. SMART is a humanized monoclonal antibody technology designed using structural information from promising murine antibodies to capture the benefits of such antibodies while overcoming many of their limitations in treating humans. A model of the murine antibody is generated using proprietary computer modeling software that predicts the shapes of antibodies. The resulting model is analyzed to identify key amino acids most responsible for maintaining the shape of the CDRs. The identified murine amino acids are substituted into the human framework of the SMART antibody with murine CDRs in order to maintain their ability to bind well to the target. The resulting SMART antibody retains most or all of the binding ability of the murine antibody, but is about 90% human. The company's Zenapax humanized antibody has been approved in the U.S. and the European Union for prevention of acute organ rejection in patients receiving kidney transplants. Zenapax is the first humanized monoclonal antibody to receive FDA marketing approval. PDLI receives royalties on sales of Zenapax, which is marketed by Hoffman-La Roche. As of December 2000, Zenapax was also in clinical trials for other disorders, including heart transplantation, pediatric kidney transplants, in combination with Roche's drug CellCept in kidney transplants, and for treatment of graft-versus-host disease in transplants. Also in development is Nuvion (SMART Anti-CD3 Antibody) to treat autoimmune disease. Although it targets the same diseases as Zenapax, Nuvion is believed to be more potent than Zenapax. At Dec. 31, 2000, PDLI had completed a Phase I trial on its humanized Anit-IL-4 antibody, which blocks the effects of interleukin 4, believed to have a link to allergies and asthma. PDL planned to conduct a Phase II trial in asthma patients. Based on an agreement with GlaxoSmithKline (GS), GS agreed to share in future development costs and potential product sales and profits, and agreed to pay a milestone fee upon achieving certain clinical milestones. INCORPORATED in Delaware July 24, 1986. OFFICE- 34081 Campus Drive, Fremont, CA, USA 94555 (Tel.: 510-574-1400). WEBSITE- http://www.pdl.com. | |
IMPORTANT DISCLAIMER: By reading any of the material on this website you agree to our DISCLAIMER: The Magi Society, Magi Astrologers Worldwide Corporation make no claims whatsoever concerning the validity of the information provided herein, and will not be held liable for any use thereof. No information or opinion expressed here is a solicitation to buy or sell securities, bonds, real estate, commodities, options, futures or any financial instruments whatsoever.
Back to first trade date main page
Back to financial astrology page
© 1999-2004 by Magi Astrologers Worldwide Corporation. All Rights Reserved.